This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXMPED0C0KP_M.jpg
Incyte announced earnings per share of $0.23 on revenue of $620.6M. Analysts polled by Investing.com anticipated EPS of $0.52 on revenue of $621M.
Incyte shares are up 1% from the beginning of the year, still down 17.32% from its 52 week high of $110.32 set on July 7. They are under-performing the S&P Global (NYSE:SPGI) 100 which is up 5.9% from the start of the year.
Incyte’s report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Pfizer had beat expectations on October 27 with third quarter EPS of $0.72 on revenue of $12.13B, compared to forecast for EPS of $0.71 on revenue of $12.31B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
